Effects of magnesium supplementation on improving hyperglycemia, hypercholesterolemia, and hypertension in type 2 diabetes: A pooled analysis of 24 randomized controlled trials
Xu L, Li X, Wang X, Xu M
Frontiers in nutrition · 16 citations
How it was studied
- Design
- Systematic review (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Natural Science Foundation of China
- Grants
- National Natural Science Foundation of China (32102553)
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2023-01-18 · Front Nutr · vol. 9 · p. 1020327
- Publisher
- Frontiers Media
- Cited
- 25 citations · more than 92% of similar papers · 3.1× the field average
- Impact
- Top 10% most cited in its field
- References
- 76 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Neurological Disorders and Treatments
- Keywords
- Medicine, Type 2 diabetes, Diabetes mellitus, Randomized controlled trial, Internal medicine, Magnesium, Endocrinology, Chemistry
4 authors
From CN, US
- Lianbin XuQingdao Agricultural University
- Xiuli LiQingdao Agricultural University
- Xinhui WangZhejiang University
- Mingqing Xu · correspondingHarvard University; Shanghai Jiao Tong University; Center for Systems Biology
Abstract
Background
Previous studies have demonstrated that diabetes is often accompanied with lower magnesium status. However, practical details regarding the influences of magnesium intervention on hyperglycemia, hypercholesterolemia, and hypertension in type 2 diabetes (T2D) need to be further investigated.
Methods
Web of Science, ScienceDirect, and PubMed were searched for relevant literatures published through April 30, 2022, and high-quality data were pooled to evaluate the effects of magnesium supplementation on glycemic, circulating lipids, and blood pressure control in T2D, and to explore the associated practical details.
Results
Pooled analyses of 24 randomized controlled trials with 1,325 T2D individuals revealed that subjects who received magnesium supplementation had statistically significant reductions in fasting plasma glucose, glycated hemoglobin, systolic blood pressure and diastolic blood pressure, with WMD values of -0.20 mM (95% CI: -0.30, -0.09), -0.22% (95% CI: -0.41, -0.03), -7.69 mmHg (95% CI: -11.71, -3.66) and -2.71 mmHg (95% CI: -4.02, -1.40), respectively. Detailed subgroup analyses demonstrated that health status of participants including age, body mass index, country, duration of disease, baseline magnesium level and baseline glycemic control condition as well as magnesium formulation, dosage and duration of intervention influenced the effects of magnesium addition. Dose-effect analysis showed that 279 mg/d for 116 d, 429 mg/d for 88 d and 300 mg/d for 120 d are the average optimal dosages and durations for improving glycemic, circulating lipids, and blood pressure controls, respectively.
Conclusion
Our findings provide clinically relevant information on the adjuvant therapy of magnesium for improving hyperglycemia, hypercholesterolemia, and hypertension in T2D.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.